Androgen control of an inhibitory modulator of phosphodiesterase in rat epididymis and prostate

Distinct actions of testicular endocrine and lumicrine signaling on the proximal epididymal transcriptome

The epididymal function and gene expression in mammals are under the control of the testis. Sex steroids are secreted from the testis and act on the epididymis in an endocrine manner. There is another, non-sex steroidal secreted signaling, named lumicrine signaling, in which testis-derived secreted proteins go through the male reproductive tract and act on the epididymis. The effects of such multiple regulations on the epididymis by the testis have been investigated for many genes. The recent development of high-throughput next-generation sequencing now enables us a further comparative survey of endocrine and lumicrine action-dependent gene expression. In the present study, testis-derived endocrine and lumicrine actions on epididymal gene expression were comparatively investigated by RNA-seq transcriptomic analyses. This investigation utilized experimental animal models in which testis-derived endocrine and/or lumicrine actions were interfered with, such as unilateral or bilateral orchidectomy. By bilateral orchidectomy, which interferes with both endocrine and lumicrine actions, 431 genes were downregulated. By unilateral orchidectomy, which also interferes with endocrine and lumicrine actions by the unilateral testis, but the endocrine action was compensated by the contralateral testis, 283 genes were downregulated. The content of such genes downregulated by unilateral orchidectomy was like those of lumicrine action-interfered efferent duct-ligation, W/Wv, and Nell2-/- mice. When genes affected by unilateral and bilateral orchidectomy were compared, 154 genes were commonly downregulated, whereas 217 genes were specifically downregulated only by bilateral orchidectomy, indicating the distinction between endocrine and lumicrine actions on the proximal epididymal transcriptome. Comparative transcriptome analyses also showed that the expressions of genes emerging since Amniota were notably impacted by bilateral orchidectomy, unilateral orchidectomy, and lumicrine action-interfering treatments; the degree of influence from these treatments varied based on the evolutionary stage beyond Amniota. These findings unveil an evolutional transition of regulated gene expression in the proximal epididymis by two different testis-derived signaling mechanisms.

Busulfan administration replicated the characteristics of the epididymal initial segment observed in mice lacking testis-epididymis lumicrine signaling

The physiological functions of the mammalian epididymis are typically regulated by the testes. In addition to sex steroids secreted by testicular Leydig cells, which act on the epididymis in an endocrine manner, there is a non-sex-steroidal signaling pathway known as the lumicrine pathway. This lumicrine signaling pathway involves ligand proteins secreted from germ cells within the testicular seminiferous tubules traversing the male reproductive tract, which induce epithelial differentiation in the epididymis. These findings prompted an inquiry into whether treatments influencing testis physiology can disrupt epididymal function by interfering with testis-epididymis communication. Busulfan, an alkylating agent commonly used to deplete testicular germ cells in reproductive biology, has not been sufficiently explored because of its effects on the epididymis. This study investigated the effects of busulfan administration on the proximal epididymis using histological and transcriptomic analyses. Notably, busulfan, as opposed to the vehicle dimethyl sulfoxide (DMSO), altered the morphology of the initial segment of the epididymis, leading to a reduction in the cell height of the luminal epithelium. RNA sequencing identified 185 significantly downregulated genes in the proximal epididymis of busulfan-administered mice compared to DMSO-administered mice. Comparative transcriptome analyses revealed similarities between the epididymal transcriptome of busulfan-administered mice and lumicrine-deficient mice, such as efferent-duct-ligated W/Wv and Nell2-/- mice. However, this differed from that of bilaterally orchidectomized mice, in which both the endocrine and lumicrine signaling pathways were simultaneously ablated. Collectively, these results suggested that the harmful effects of busulfan on the proximal epididymis are secondary consequences of the ablation of testis-epididymis lumicrine signaling.

Sex hormones modulate salbutamol-elicited long-term relaxation in isolated bovine tracheal strips

Sex hormones are of interest regarding gender differences in the clinical manifestations of airway diseases. No conclusive data are available on the sex hormone modulation of β-adrenoceptor-mediated responses on airways. To this aim, isolated preparations of bovine trachea were used to establish the sex hormone influence on salbutamol-elicited relaxation. This had 2 components, a full acute relaxation followed by a loss of efficacy, close to half of the effect. The remaining half was reverted by the β-blocker, propranolol. The loss of salbutamol-elicited relaxation might reflect the receptor desensitization, as shown by the lack of effect by subsequent administration of salbutamol, and the decrease in the immunostaining of β(2)-adrenoceptors. Sex hormones differently modified the salbutamol-elicited response. Testosterone, but not other androgens or estradiol, had a synergic effect, facilitating the acute relaxation and decreasing the loss of spasmolytic effect, associated with an increase in the latency of desensitization and a decrease in the time taken to reach long-term steady-state tone. These effects, not modified by the antiandrogen flutamide or epithelium removal, seem to be independent of a modulation of β(2)-adrenoceptor desensitization. Testosterone also relaxed preparations with desensitized β-adrenoceptor. Therefore, testosterone modulates tracheal smooth muscle tone, facilitating bronchodilation caused by β(2)-adrenoceptor agonists which might be of pharmacological interest.

Effect of pregnancy on PDE4 cAMP-specific phosphodiesterase messenger ribonucleic acid expression in human myometrium

In light of the important role of the second messengers cAMP and cGMP in the mechanism of relaxation in the human myometrium, specific regulation of the phosphodiesterase (PDE) enzymatic system responsible for cyclic nucleotide inactivation is essential. We previously identified in the human myometrium PDE4 cAMP-specific PDE as by far the most abundant isoform. Here we have studied the expression patterns of mRNAs for the four cloned human PDE4 genes in the myometria of pregnant and non-pregnant women. Concurrent expression of the PDE4A, 4B, 4C and 4D genes is demonstrated. We found that the PDE4D transcripts are the most prominently expressed. PDE4A and PDE4B mRNAs also are markedly abundant, whereas lower expression is observed for PDE4C mRNAs. Interestingly, we showed that transcripts of PDE4B2 are more abundant in the myometria of pregnant women than in non-pregnant women, whereas no difference between the two tissues was detected for PDE4A, 4C and 4D mRNAs. Cultured human myometrial cells, which present a high level of PDE4 activity and express the four PDE4 mRNA subtypes, provide us with an appropriate model to further evaluate whether the level of expression of the PDE 4B2 mRNA subtype is under hormonal regulation.

Cyclic adenosine 3',5'-monophosphate-phosphodiesterases in epididymis and prostate of castrate and of aged rats

The activities of the low-Km and high-Km forms of cyclic AMP phosphodiesterase (PDE) were determined in extracts prepared from epididymis and prostate taken from adult (10-12 months) and from aged (32-35 months) rats. The maximum velocity V of low-Km PDE in the epididymis of normal adult rats (approx. 300 pmoles/min per mg protein) was increased after castration by 80%, whereas V of the high-Km form remained unchanged, suggesting that only the low-Km PDE is subject to regulation by the animals' endocrine status. In the epididymis of aged rats V of low-Km PDE was unchanged, whereas V of high-Km PDE (approx. 3000 pmoles/min per mg protein) was decreased by 40%; in the prostate of aged rats V of both low-Km (approx. 225 pmoles/min per mg protein), and of high-Km PDE (approx. 1500 pmoles/min per mg protein) were decreased by 50-60%. The absence of interdependence of the two forms of the enzyme in their response to changes in environmental conditions in each organ suggests different mechanisms of control of their activities and adds validity to the reported age-related decline of low-Km-PDE activity in prostate.

Control of low Km cyclic adenosine 3',5'-monophosphate-phosphodiesterase in prostate and heart of adult and aged rats

The activity of low Km cAMP-phosphodiesterase (PDE) was determined in extracts of prostate and heart of adult (10-12 months old) and aged (32-35 months old) Sprague-Dawley rats; the enzyme's response to endogenous inhibitors extracted from the two organs was analyzed by kinetic studies. Different mechanisms of inhibition, non-competitive in prostate and competitive in heart extracts, indicate organ-specificity of the inhibitor. The decreased PDE activity in organ extracts of aged rats and its continued sensitivity to the endogenous inhibitor suggest an age-associated impairment of the tissues' ability to terminate cAMP-mediated signals.

[Cyclic nucleotide phosphodiesterase in vertebrates]

The cellular concentration of cyclic nucleotides is largely dependent upon the activity of the enzymatic system responsible for their degradation: cyclic nucleotide phosphodiesterase. This enzymatic system thus plays a crucial role in the regulation of the multiple functions which are modulated by cyclic nucleotides in the organism. Many methodological problems, as well as the complexity of the phosphodiesterase system have long maintained a confusion in this field. Recent progresses (purification to homogeneity of some enzymatic forms, discovery of regulatory mechanisms, particularly) have brought a considerable evolution in the knowledge of the system. It is now well established that cyclic nucleotide phosphodiesterase exists under several isoenzymatic forms, the properties and distribution of which largely differ from a tissue to another. Some of these forms are relatively well characterized, while the representativity of others is still discussed. The significance of this multiplicity of isoenzymes, and their interrelationships are presently under study. A very interesting aspect in the study of this enzymatic system is that it is submitted to several physiological regulatory processes. Recent studies on this point suggest that phosphodiesterase might play a major role in the response of the organism to several hormones. These fundamental studies of phosphodiesterase system find a most interesting application in the pharmacological field. Indeed, numerous synthetic compounds which inhibit the enzyme present a strong pharmacological interest.